Merger Builds Japanese Firm For Drug Development Services
This article was originally published in PharmAsia News
A Japanese merger is expected to lead to an expanded list of services in support of local drug development. An equity stake in Medical Collective Intelligence has brought Itochu into the business of marketing support to drug makers. The merged firm plans to conduct studies pharmaceutical companies have been asking for to determine areas of large need for drug development. The new company also plans to offer a full range of services for the drug industry. (Click here for more - a subscription may be required
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.